Literature DB >> 19413454

TAT-based drug delivery system--new directions in protein delivery for new hopes?

Matan Rapoport1, Haya Lorberboum-Galski.   

Abstract

There has been great progress in the use of TAT-based drug delivery systems for the delivery of different macromolecules into cells in vitro and in vivo, thus circumventing the bioavailability barrier that is a problem for so many drugs. There are many advantages to using this system, such as the ability to deliver these cargoes into all types of cells in culture and into all organs in vivo. This system can even deliver cargoes into the brain across the blood-brain barrier. In addition, the ability to target specific intracellular sub-localizations such as the nuclei, the mitochondria and lysosomes further expands the possibilities of this drug delivery system to the development of sub-cellular organelle-targeted therapy. The therapeutic applications seem almost unlimited, and the use of the TAT-based delivery system has extended from proteins to a large variety of cargoes such as oligonucleotides, imaging agents, low molecular mass drugs, nanoparticles, micelles and liposomes. In this review the most recent advances in the use of the TAT-based drug delivery system will be described, mainly discussing TAT-mediated protein delivery and the use of the TAT system for enzyme replacement therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19413454     DOI: 10.1517/17425240902887029

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  22 in total

1.  Lipid membrane editing with peptide cargo linkers in cells and synthetic nanostructures.

Authors:  Hua Pan; Jacob W Myerson; Olena Ivashyna; Neelesh R Soman; Jon N Marsh; Joshua L Hood; Gregory M Lanza; Paul H Schlesinger; Samuel A Wickline
Journal:  FASEB J       Date:  2010-03-24       Impact factor: 5.191

Review 2.  Targeting antibodies to the cytoplasm.

Authors:  Andrea L J Marschall; André Frenzel; Thomas Schirrmann; Manuela Schüngel; Stefan Dübel
Journal:  MAbs       Date:  2011-01-01       Impact factor: 5.857

3.  Oral treatment with the d-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer's Disease transgenic mice.

Authors:  Susanne Aileen Funke; Thomas van Groen; Inga Kadish; Dirk Bartnik; Luitgard Nagel-Steger; Oleksandr Brener; Torsten Sehl; Renu Batra-Safferling; Christine Moriscot; Guy Schoehn; Anselm H C Horn; Andreas Müller-Schiffmann; Carsten Korth; Heinrich Sticht; Dieter Willbold
Journal:  ACS Chem Neurosci       Date:  2010-08-02       Impact factor: 4.418

4.  Cardiomyopathy of Friedreich's ataxia: use of mouse models to understand human disease and guide therapeutic development.

Authors:  R Mark Payne; P Melanie Pride; Clifford M Babbey
Journal:  Pediatr Cardiol       Date:  2011-03-01       Impact factor: 1.655

Review 5.  Methods for gene transfer to the central nervous system.

Authors:  Boris Kantor; Rachel M Bailey; Keon Wimberly; Sahana N Kalburgi; Steven J Gray
Journal:  Adv Genet       Date:  2014       Impact factor: 1.944

6.  Molecular mechanisms in the dramatic enhancement of HIV-1 Tat transduction by cationic liposomes.

Authors:  Guan-Han Li; Wenxue Li; Russell J Mumper; Avindra Nath
Journal:  FASEB J       Date:  2012-03-23       Impact factor: 5.191

7.  The effect of systemic PTEN antagonist peptides on axon growth and functional recovery after spinal cord injury.

Authors:  Yosuke Ohtake; Dongsun Park; P M Abdul-Muneer; Hui Li; Bin Xu; Kartavya Sharma; George M Smith; Michael E Selzer; Shuxin Li
Journal:  Biomaterials       Date:  2014-03-12       Impact factor: 12.479

8.  A peptide targeting an interaction interface disrupts the dopamine D1-D2 receptor heteromer to block signaling and function in vitro and in vivo: effective selective antagonism.

Authors:  Ahmed Hasbi; Melissa L Perreault; Maurice Y F Shen; Lucia Zhang; Ryan To; Theresa Fan; Tuan Nguyen; Xiaodong Ji; Brian F O'Dowd; Susan R George
Journal:  FASEB J       Date:  2014-07-25       Impact factor: 5.191

Review 9.  Peptide Pharmacological Approaches to Treating Traumatic Brain Injury: a Case for Arginine-Rich Peptides.

Authors:  Li Shan Chiu; Ryan S Anderton; Neville W Knuckey; Bruno P Meloni
Journal:  Mol Neurobiol       Date:  2016-11-14       Impact factor: 5.590

Review 10.  Biofunctionalized nanoneedles for the direct and site-selective delivery of probes into living cells.

Authors:  Kyungsuk Yum; Min-Feng Yu; Ning Wang; Yang K Xiang
Journal:  Biochim Biophys Acta       Date:  2010-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.